A randomised, placebo-controlled, double-blind, double-dummy, crossover study to assess the onset of action of two inhalations of Symbicort 160/4.5 mcg, compared with two inhalations of Seretide 25/250 mcg, two inhalations of Ventoline 100 mcg, and placebo, delivered by pressurised metered dose inhalers, in patients with chronic obstructive pulmonary disease (COPD).
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
No locations available